Navigation Links
Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
Date:11/12/2013

ll," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros' unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims and the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Corporation Reports Third Quarter 2013 Financial Results
2. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
3. Omeros to Present at the 12th Annual Needham Healthcare Conference
4. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
5. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
6. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
7. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
8. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
9. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
10. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
11. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 28 f-star, an antibody,engineering company developing novel antibodies ... today announced that it,has raised EUR 3.0 million from ... financing round, originally co-led by Aescap Venture and Atlas ... Series A round,increases to EUR 9.0 million. In total, ...
... Va., Nov. 28 LifeNet Health,a leading ... with IMS (Integrated Medical Systems International, Inc.), ... for LifeNet,Health customers, improving the tracking of ... the development, marketing, distribution, and,support of a ...
... Fla., Nov. 28 News briefs concerning the,economic and ... Tampa Bay,Partnership:, SRI Launches First Major Project to ... a five-year, $36.5 million contract,to develop a Maritime Domain ... technologies for improving port security in,the United States. The ...
Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3LifeNet Health and IMS Announce Partnership 2Highlights of Economic and Business Growth in the Tampa Bay Region 2Highlights of Economic and Business Growth in the Tampa Bay Region 3Highlights of Economic and Business Growth in the Tampa Bay Region 4
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... 2012 BONESUPPORT, ein aufstrebendes Unternehmen im ... und Instrumentenzusätze für orthopädische Chirurgie, gab heute ... Marktführerschaft im Bereich Innovation und Technologie unter ... als einer der Top 100-Gewinner für den ...
... School of Dentistry have made an important connection ... high blood pressure. Production of the molecule Brain-Derived ... blood pressure-sensing nerve cells during hypertension. The study, ... Research , may someday have implications for the ...
... Press coverage of synthetic biology in the United States and ... report released today by the Synthetic Biology Project at the ... Trends in American and European Press Coverage of Synthetic Biology: ... US-EU press coverage between 2003 and 2008. Synthetic biology, an ...
Cached Biology News:BONESUPPORT für 2012 Top 100 Global Award von Red Herring ausgewählt 2BONESUPPORT für 2012 Top 100 Global Award von Red Herring ausgewählt 3New report finds increase in media coverage of synthetic biology 2
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... K-12 derivatives that have mutations in both ... (gor) genes, which greatly enhances disulfide bond ... that expression in Origami(DE3) yielded 10-fold more ... though overall expression levels were similar (1). ...
Biology Products: